UBT251 for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 2 Feb 2026: Trial started, NCT07395687
  2. 9 Feb 2026: Trial registered, NCT07395687

The trials

NCT07395687: A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

State
Under way
Phase
Phase 2
People
333 planned
Started
2 Feb 2026
Primary completion
14 Jan 2027
Arms
Part A - UBT251, Part B - Arm A (UBT251), Part B - Arm B (UBT251), Part B - Arm C (UBT251), Part B - Arm D (UBT251), Part B - Arm E (UBT251), Part C - UBT251 dose 1, Part C - UBT251 dose 2, Part C - UBT251 dose 3
Results
None posted
  1. 2 Feb 2026: Trial started
  2. 9 Feb 2026: Trial registered

NCT07806851: UBT251 Injection Phase Ⅲ Study (OSA-PAP)

State
Not started
Phase
Phase 3
People
150 planned
Started
10 Oct 2026
Primary completion
Mar 2029
Arms
UBT251 Dose 1, UBT251 Dose 2
Results
None posted
  1. 8 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.